Methods: We performed a pooled analysis of several approved phase 3 trials as first-line immunotherapy for non-HER2-positive/HER2-negative advanced or metastatic GC or gastroesophageal junction cancer (GEJC) based on PD-L1 expression in segments with different expression levels. Here, ERBB2 is linked to gastric cancer.